Immunome (NASDAQ:IMNM) just reported results for the fourth quarter of 2023.
- Immunome reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -28 cents.
- The company reported revenue of $3.83 million.
- This was 84.83% better than the analyst estimate for revenue of $2.07 million.